Long-Term Expression and Safety of Administration of AAVrh.10hCLN2 to the Brain of Rats and Nonhuman Primates for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis

Abstract

Late infantile neuronal ceroid lipofuscinosis (LINCL), a fatal, lysosomal storage disorder caused by mutations in the CLN2 gene, results in a deficiency of tripeptidyl-peptidase I (TPP-I) activity in neurons. Our prior studies showed that delivery of the human CLN2 cDNA directly to the CNS, using an adeno-associated virus serotype 2 (AAV2) vector, is safe in children with LINCL. As a second-generation strategy, we have demonstrated that AAVrh.10hCLN2, a rhesus-derived AAV vector, mediates wide distribution of TPP-I through the CNS in a murine model. This study tests the hypothesis that direct administration of AAVrh.10hCLN2 to the CNS of rats and nonhuman primates at doses scalable to humans has an acceptable safety profile and mediates significant CLN2 expression in the CNS. A dose of 10¹¹ genome copies (GC) was administered bilaterally to the striatum of Sprague Dawley rats with sacrifice at 7 and 90 days with no significant impact except for mild vector-related histopathological changes at the site of vector administration. A dose of 1.8×10¹² GC of AAVrh.10hCLN2 was administered to the CNS of 8 African green monkeys. The vector-treated monkeys did not differ from controls in any safety parameter except for mild to moderate white matter edema and inflammation localized to the administration sites of the vector. There were no clinical sequelae to these localized findings. TPP-I activity was >2 SD over background in 31.7±8.1% of brain at 90 days. These findings establish the dose and safety profile for human clinical studies for the treatment of LINCL with AAVrh.10hCLN2.

Sondhi and colleagues demonstrate that administration of Adeno-Associated Viral vector serotype rh10 encoding the human CLN2 gene into the striatum of rats and the CNS of African Green Monkeys results in efficient expression of tripeptidyl peptidase I (TPP-I), with minimal adverse effects.

Get full access to this article

View all access options for this article.

References

Boustany

R.M.

1996. Batten disease or neuronal ceroid lipofuscinosis. Handbook of Clinical Neurology. Moser

H.W.

Elsevier Science: New York, 671–700.

Boutin

, Monteilhet

, Veron

et al. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum. Gene Ther., 21:704–712.

Calcedo

, Vandenberghe

L.H.

, Gao

et al. 2009. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis., 199:381–390.

Calcedo

, Morizono

, Wang

et al. 2011. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin. Vaccine Immunol., 18:1586–1588.

Cearley

C.N.

, Wolfe

J.H.

2006. Transduction characteristics of adeno-associated virus vectors expressing Cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol. Ther., 13:528–537.

Crystal

R.G.

, Sondhi

, Hackett

N.R.

et al. 2004. Clinical protocol: Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum. Gene Ther., 15:1131–1154.

Daly

T.M.

, Vogler

, Levy

et al. 1999. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. Natl. Acad. Sci. U.S.A., 96:2296–2300.

B.P.

, Heguy

, Hackett

N.R.

et al. 2006. High levels of persistent expression of α₁-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol. Ther., 13:67–76.

Ezaki

, Tanida

, Kanehagi

et al. 1999. A lysosomal proteinase, the late infantile neuronal ceroid lipofuscinosis gene (CLN2) product, is essential for degradation of a hydrophobic protein, the subunit c of ATP synthase. J. Neurochem., 72:2573–2582.

10.

Gao

, Alvira

M.R.

, Somanathan

et al. 2003. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl. Acad. Sci. U.S.A., 100:6081–6086.

11.

Hackett

N.R.

, Redmond

D.E.

, Sondhi

et al. 2005. Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates. Hum. Gene Ther., 16:1484–1503.

12.

Haltia

2003. The neuronal ceroid-lipofuscinoses. J. Neuropathol. Exp. Neurol., 62:1–13.

13.

Herzog

C.D.

, Dass

, Gasmi

et al. 2008. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol. Ther., 16:1737–1744.

14.

, Busuttil

R.W.

, Lipshutz

G.S.

2010. RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J. Gene Med., 12:766–778.

15.

Lin

, Lobel

2001. Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis. Biochem. J., 357:49–55.

16.

Manno

C.S.

, Pierce

G.F.

, Arruda

V.R.

et al. 2006. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 12:342–347.

17.

McPhee

S.W.

, Janson

C.G.

, Li

et al. 2006. Immune responses to AAV in a phase I study for Canavan disease. J. Gene Med., 8:577–588.

18.

Nathwani

A.C.

, Gray

J.T.

, McIntosh

et al. 2007. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood, 109:1414–1421.

19.

Rawlings

N.D.

, Barrett

A.J.

1999. Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuronal ceroid lipofuscinosis. Biochim. Biophys. Acta, 1429:496–500.

20.

Sleat

D.E.

, Donnelly

R.J.

, Lackland

et al. 1997. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science, 277:1802–1805.

21.

Sleat

D.E.

, Gin

R.M.

, Sohar

et al. 1999. Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. Am. J. Hum. Genet., 64:1511–1523.

22.

Sleat

D.E.

, Wiseman

J.A.

, El-Banna

et al. 2004. A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration. J. Neurosci., 24:9117–9126.

23.

Sondhi

, Hackett

N.R.

, Apblett

R.L.

et al. 2001. Feasibility of gene therapy for late neuronal ceroid lipofuscinosis. Arch. Neurol., 58:1793–1798.

24.

Sondhi

, Peterson

D.A.

, Giannaris

E.L.

et al. 2005. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther., 12:1618–1632.

25.

Sondhi

, Hackett

N.R.

, Peterson

D.A.

et al. 2007. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol. Ther., 15:481–491.

26.

Sondhi

, Peterson

D.A.

, Edelstein

A.M.

et al. 2008. Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Exp. Neurol., 213:18–27.

27.

Steinfeld

, Heim

, von Gregory

et al. 2002. Late infantile neuronal ceroid lipofuscinosis: Quantitative description of the clinical course in patients with CLN2 mutations. Am. J. Med. Genet., 112:347–354.

28.

Vandenberghe

L.H.

, Breous

, Nam

H.J.

et al. 2009. Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints. Gene Ther., 16:1416–1428.

29.

Vines

D.J.

, Warburton

M.J.

1999. Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I. FEBS Lett., 443:131–135.

30.

Williams

R.E.

, Gottlob

, Lake

B.D.

et al. 1999. Classic late infantile NCL. The Neuronal Ceroid Lipofuscinosis (Batten Disease) Goebel

H.H.

IOS Press: Fairfax, VA, 37–54.

31.

Wisniewski

, Kida

, Golabek

A.A.

et al. 2001. Neuronal Ceroid Lipofuscinosis: Classification and Diagnosis. Academic Press: New York, 1–34.

32.

Worgall

, Kekatpure

M.V.

, Heier

et al. 2007. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology, 69:521–535.

33.

Worgall

, Sondhi

, Hackett

N.R.

et al. 2008. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther., 19:463–474.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.05 MB

0.09 MB

0.08 MB